N@N

Market Maker Surveillance Report. AXK, FONR, KERX, RDEA, JMGE, SEFE, Winning Stocks With Lowest Price Friction For Monday, Apr

April 23, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3714 companies with "abnormal" market making, 1568 companies with positive Friction Factors and 4220 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. ACCELER8 TECHNOLOGY CORP (AMEX:AXK), FONAR CORP (NASDAQ:FONR), KERYX BIOPHARMACEUTICALS (NASDAQ:KERX), ARDEA BIOSCIENCES, INC. (NASDAQ:RDEA), JMG EXPLORATION INC (OTC:JMGE), (OTCBB:SEFE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  AXK     $1.700    163.44%   214,122      27.22%    171,043      21.74%    43,079       253     
  FONR    $1.500    30.36%    1,149,468    51.82%    1,058,834    47.73%    90,634       604     
  KERX    $0.380    27.94%    7,068,235    53.28%    6,186,696    46.63%    881,539      23,198  
  RDEA    $10.770   51.70%    16,344,565   57.46%    11,888,923   41.79%    4,455,642    4,137   
  JMGE    $0.630    90.00%    126,417      43.58%    61,610       21.24%    64,807       1,029   
  SEFE    $0.560    32.00%    7,455,367    46.38%    5,471,358    34.04%    1,984,009    35,429  

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows AXK with a dollar gain Monday of $1.70000 and a Friction Factor of 253 shares. That means that it only took 253 more shares of buying than selling to move AXK higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

ACCELER8 TECHNOLOGY CORP (AMEX:AXK) - Accelr8 Technology Corporation develops materials and instrumentation for applications in medical instrumentation, basic research, drug discovery, and bio-detection in the United States. It manufactures and markets OptiChem surface coatings for use in microarraying components. The company is also developing a program to integrate OptiChem surface chemistry, QuanDx light-scattering quantitative assay instrumentation, and YoDx assay acceleration process into the BACcel system for rapid bacterial identification and antibiotic resistance testing. Accelr8 Technology Corporation was founded in 1982 and is based in Denver, Colorado.

FONAR CORP (NASDAQ:FONR) - FONAR Corporation engages in the design, manufacture, sale, and service of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases. It provides Upright Multi-positional MRI scanners, which allow patients to be scanned in a weight-bearing condition, such as standing, sitting, or bending in any position that causes symptoms; and FONAR 360 MRI scanner, a diagnostic scanner. The company, through its wholly owned subsidiary, Health Management Corporation of America, also offers management services to imaging facilities, such as development, administration, and leasing of office space, facilities, and medical equipment; provision of supplies; staffing and supervision of non-medical personnel; legal services; accounting, billing, and collection; and the development and implementation of practice growth and marketing strategies. It serves private scanning centers and hospitals. As of June 30, 2010, the company managed 10 diagnostic imaging facilities located in the states of New York, Georgia, and Florida. FONAR Corporation was founded in 1978 and is based in Melville, New York.

KERYX BIOPHARMACEUTICALS (NASDAQ:KERX) - Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. The companys products under development include KRX-0401 (perifosine), a phase III clinical stage product, which is an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects other pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival; and Zerenex (ferric citrate), an oral iron-based compound, which completed phase II clinical stage for the treatment of hyperphosphatemia in patients with end-stage renal disease. It has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products. Keryx Biopharmaceuticals, Inc. was founded in 1998 and is based in New York, New York.

ARDEA BIOSCIENCES, INC. (NASDAQ:RDEA) - Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), and cancer in the United States. The companys products include RDEA594, a Phase IIb clinical trial product for the treatment of gout; RDEA684, a preclinical trial product for the treatment of gout with hyperuricemia; RDEA806, a non-nucleoside reverse transcriptase inhibitor, which completed Phase II clinical trial for the treatment of patients with HIV; and RDEA427, which is in first-in-human micro-dose pharmacokinetic study for the treatment of HIV infection. It is evaluating RDEA119, an inhibitor of Mitogen-activated ERK kinase (MEK), which is in Phase I/II study in combination with sorafenib and as a single agent in a Phase I study, both in advanced cancer patients. The company has a license agreement with Bayer to develop and commercialize MEK inhibitors for various indications. Ardea Biosciences, Inc. is based in San Diego, California.

JMG EXPLORATION INC (OTC:JMGE) - JMG Exploration, Inc. explores and develops oil and natural gas properties in the United States and Canada. As of December 31, 2009, it owned 77.5% working interest on the Pinedale anticline natural gas reserves in the Jonah field of the Green River Basin in west central Wyoming. The company was incorporated in 2004 and is based in Pasadena, California.

(OTCBB:SEFE) -

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net